Nurix Therapeutics, Inc. (NRIX)
15.95
-9.87
(-38.23%)
USD |
NASDAQ |
Nov 04, 16:00
15.97
+0.02
(+0.13%)
After-Hours: 07:29
Nurix Therapeutics Market Cap : 1.742B for Nov. 4, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| November 04, 2026 | 1.742B |
| November 03, 2026 | 2.820B |
| November 02, 2026 | 2.806B |
| October 30, 2026 | 2.927B |
| October 29, 2026 | 2.962B |
| October 28, 2026 | 2.977B |
| October 27, 2026 | 2.916B |
| October 26, 2026 | 2.790B |
| October 23, 2026 | 2.767B |
| October 22, 2026 | 2.786B |
| October 21, 2026 | 2.841B |
| October 20, 2026 | 2.850B |
| October 19, 2026 | 2.722B |
| October 16, 2026 | 2.667B |
| October 15, 2026 | 2.725B |
| October 14, 2026 | 2.585B |
| October 13, 2026 | 2.417B |
| October 12, 2026 | 2.420B |
| October 09, 2026 | 2.441B |
| October 08, 2026 | 2.425B |
| October 07, 2026 | 2.357B |
| October 06, 2026 | 2.344B |
| October 05, 2026 | 2.373B |
| October 02, 2026 | 2.384B |
| October 01, 2026 | 2.420B |
| Date | Value |
|---|---|
| September 30, 2026 | 2.459B |
| September 29, 2026 | 2.455B |
| September 28, 2026 | 2.455B |
| September 25, 2026 | 2.386B |
| September 24, 2026 | 2.453B |
| September 23, 2026 | 2.476B |
| September 22, 2026 | 2.662B |
| September 21, 2026 | 2.635B |
| September 18, 2026 | 2.638B |
| September 17, 2026 | 2.644B |
| September 16, 2026 | 2.608B |
| September 15, 2026 | 2.575B |
| September 14, 2026 | 2.646B |
| September 11, 2026 | 2.603B |
| September 10, 2026 | 2.677B |
| September 09, 2026 | 2.723B |
| September 08, 2026 | 2.710B |
| September 04, 2026 | 2.711B |
| September 03, 2026 | 2.626B |
| September 02, 2026 | 2.678B |
| September 01, 2026 | 2.700B |
| August 31, 2026 | 2.673B |
| August 28, 2026 | 2.718B |
| August 27, 2026 | 2.787B |
| August 26, 2026 | 2.770B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Gilead Sciences, Inc. | 216.53B |
| ACADIA Pharmaceuticals, Inc. | 3.696B |
| Alnylam Pharmaceuticals, Inc. | 21.56B |
| Anika Therapeutics, Inc. | 273.01M |
| Savara, Inc. | 957.16M |
Market Cap Related Metrics
| PE Ratio | 6.896 |
| PS Ratio | 2.456 |
| Price to Book Value | 1.799 |
| Price to Free Cash Flow | 4.662 |
| Price | 15.95 |
| Earnings Yield | 14.50% |
| Operating PE Ratio | 5.952 |
| Normalized PE Ratio | 6.896 |